Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Shawn Harriman"'
Autor:
Dominic Scaglioni, Francesco Catapano, Matthew Ellis, Silvia Torelli, Darren Chambers, Lucy Feng, Matthew Beck, Caroline Sewry, Mauro Monforte, Shawn Harriman, Erica Koenig, Jyoti Malhotra, Linda Popplewell, Michela Guglieri, Volker Straub, Eugenio Mercuri, Laurent Servais, Rahul Phadke, Jennifer Morgan, Francesco Muntoni
Publikováno v:
Acta Neuropathologica Communications, Vol 9, Iss 1, Pp 1-17 (2021)
Abstract During the last decade, multiple clinical trials for Duchenne muscular dystrophy (DMD) have focused on the induction of dystrophin expression using different strategies. Many of these trials have reported a clear increase in dystrophin prote
Externí odkaz:
https://doaj.org/article/0bb99a8919a34521a7b32c5a0a245087
Autor:
Feng Yin, Chris DeCiantis, Jan Pinkas, Biplab Das, Frank Wang, Nancy Zheng, David Hahn, Aniruddha Amrite, Diana Adhikari, Cheikh Kane, Jack Sikora, Justin Pittman, Rebecca Wates, Elizabeth Shaheen, Shawn Harriman
Publikováno v:
Bioanalysis. 15:43-52
Aim: PYX-201 is a novel antibody–drug conjugate targeting the extra domain B splice variant of fibronectin in the tumor microenvironment. Accurate quantification of PYX-201 is critical for PYX-201 pharmacokinetics profiling in preclinical studies.
Autor:
Feng Yin, Chris DeCiantis, Jan Pinkas, Biplab Das, Frank Wang, Nancy Zheng, David Hahn, Aniruddha Amrite, Jianwen Feng, Diana Adhikari, Cheikh Kane, Jack Sikora, Justin Pittman, Rebecca Wates, Elizabeth Shaheen, Shawn Harriman
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914339de208a4ceb56be8f6a136f128c
https://doi.org/10.2139/ssrn.4417062
https://doi.org/10.2139/ssrn.4417062
Autor:
Samantha Foley, Shawn Harriman, Jianbo Zhang, Marie Claire Mukashyaka, Bryan Mastis, John R Hadcock, Jenna Wood, Chia-Ling Wu, Nino Jungels, Kristin Ha, Mohammad Shadid, Huadong Sun
Publikováno v:
Pharmaceutical Research
Purpose Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) have shown promise in treating Duchenne muscular dystrophy (DMD). We evaluated a semi-mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) model to capture the relationsh
Autor:
Feng Yin, Diana Adhikari, Minghao Sun, M. Shane Woolf, Eric Ma, William Mylott, Elizabeth Shaheen, Shawn Harriman, Jan Pinkas
Publikováno v:
Journal of Chromatography B. 1223:123715
Autor:
Stephen G. Davies, Angela J. Russell, Enrico Emer, Sarah E. Squire, Maria Chatzopoulou, Francis Xavier Wilson, Lee Moir, Anne-Sophie Casagrande, Kay E. Davies, Jessica A. Rowley, Graham Michael Wynne, Cristina Lecci, Shawn Harriman
Publikováno v:
ACS Med Chem Lett
[Image: see text] Utrophin modulation is a disease-modifying therapeutic strategy for Duchenne muscular dystrophy that would be applicable to all patient populations. To improve the suboptimal profile of ezutromid, the first-in-class clinical candida
Autor:
Arran Babbs, Jessica A. Rowley, Stephen G. Davies, Adam Berg, Benjamin Edwards, Simon Guiraud, Graham Michael Wynne, Cristina Lecci, Maria Chatzopoulou, Lee Moir, Enrico Emer, Shawn Harriman, Neil Robinson, Francis Xavier Wilson, David Peters, Sarah E. Squire, D. Elsey, Kay E. Davies, Angela J. Russell, Jonathon M. Tinsley
Publikováno v:
Journal of Medicinal Chemistry. 63:7880-7891
Utrophin modulation is a promising therapeutic strategy for Duchenne muscular dystrophy (DMD), which should be applicable to all patient populations. Following on from ezutromid, the first-generation utrophin modulator, we describe the development of
Autor:
Francesco Muntoni, Stefan Spinty, Gary Layton, Imelda Hughes, Kay E. Davies, Bina Tejura, Jonathon M. Tinsley, Helen Roper, Shawn Harriman
Publikováno v:
Clinical Pharmacology in Drug Development. 8:922-933
Ezutromid (SMT C1100) is a small-molecule utrophin modulator that was developed to treat Duchenne muscular dystrophy (DMD). Previous clinical trials of this agent revealed lower exposure in DMD patients compared with healthy volunteers, which may ref
Autor:
F. Catapano, Jennifer E. Morgan, Caroline Sewry, Matthew Ellis, D. Scaglioni, Erica Koenig, Matthew Beck, Mauro Monforte, Lucy Feng, Volker Straub, Francesco Muntoni, Silvia Torelli, Eugenio Mercuri, D. Chambers, Jyoti Malhotra, Linda Popplewell, Shawn Harriman, Laurent Servais, Michela Guglieri, Rahul Phadke
Publikováno v:
Acta Neuropathologica Communications
Acta Neuropathologica Communications, Vol 9, Iss 1, Pp 1-17 (2021)
Acta Neuropathologica Communications, Vol 9, Iss 1, Pp 1-17 (2021)
During the last decade, multiple clinical trials for Duchenne muscular dystrophy (DMD) have focused on the induction of dystrophin expression using different strategies. Many of these trials have reported a clear increase in dystrophin protein follow
Autor:
Arran, Babbs, Adam, Berg, Maria, Chatzopoulou, Kay E, Davies, Stephen G, Davies, Benjamin, Edwards, David J, Elsey, Enrico, Emer, Simon, Guiraud, Shawn, Harriman, Cristina, Lecci, Lee, Moir, David, Peters, Neil, Robinson, Jessica A, Rowley, Angela J, Russell, Sarah E, Squire, Jonathon M, Tinsley, Francis X, Wilson, Graham M, Wynne
Publikováno v:
Journal of medicinal chemistry. 63(14)
Utrophin modulation is a promising therapeutic strategy for Duchenne muscular dystrophy (DMD), which should be applicable to all patient populations. Following on from ezutromid, the first-generation utrophin modulator, we describe the development of